Cardiome announces commercial launch of BRINAVESS in Canada
Cardiome Pharma announced that it received authorization from Health Canada to begin selling BRINAVESS and has subsequently launched BRINAVESS in Canada. BRINAVESS is indicated for the rapid conversion of recent onset atrial fibrillation to sinus rhythm for: non-surgery patients with AF less than 7 days; and post-cardiac surgery patients with duration of AF less than 3 days. BRINAVESS is not recommended for conversion of atrial flutter to sinus rhythm. The product is currently available on the Ontario formulary, with a broader launch anticipated in the third quarter of this year as more provinces are expected to include BRINAVESS in the provincial formularies.